OverviewChartNewsTraderScreen

HSBC Knock-Out REGN/  DE000TT6X0N4  /

Frankfurt Zert./HSBC
27/06/2024  13:20:30 Chg.+0.090 Bid13:24:35 Ask13:24:35 Underlying Strike price Expiration date Option type
62.290EUR +0.14% 62.300
Bid Size: 10,000		 62.800
Ask Size: 10,000		 Regeneron Pharmaceut... 406.7391 USD 31/12/2078 Call
GlobeNewswire 26/06 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
GlobeNewswire 26/06 Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...
GlobeNewswire 22/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 18/06 Kriya Appoints Katherine Eade as Chief Legal Officer
GlobeNewswire 18/06 Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD ...
GlobeNewswire 16/06 Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...
GlobeNewswire 13/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 11/06 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire 05/06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 04/06 Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire 03/06 FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroG...
GlobeNewswire 31/05 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire 31/05 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire 31/05 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire 31/05 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 28/05 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 23/05 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
GlobeNewswire 22/05 Invivyd Elects Two New Independent Members to its Board of Directors
GlobeNewswire 21/05 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire 20/05 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 20/05 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire 20/05 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire 20/05 Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encou...
GlobeNewswire 17/05 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...